Lu-Cheng Zhu Selected Research

LC capilliposide

1/2017

Capilliposide from Lysimachia capillipes inhibits AKT activation and restores gefitinib sensitivity in human non-small cell lung cancer cells with acquired gefitinib resistance.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lu-Cheng Zhu Research Topics

Disease

4	Neoplasms (Cancer) 08/2018 - 01/2014
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 02/2017 - 01/2017
1	Hyperthermia 08/2018
1	Ataxia Telangiectasia (Louis Bar Syndrome) 08/2018
1	Neoplasm Metastasis (Metastasis) 02/2017
1	Brain Neoplasms (Brain Tumor) 02/2017
1	Rectal Neoplasms (Rectal Cancer) 01/2014
1	Diarrhea 01/2014
1	Hand-Foot Syndrome 01/2014

Drug/Important Bio-Agent (IBA)

1	Matrix Metalloproteinases (MMPs)IBA 08/2018
1	Phosphotransferases (Kinase)IBA 08/2018
1	Reactive Oxygen Species (Oxygen Radicals)IBA 08/2018
1	AfatinibIBA 02/2017
1	LC capilliposideIBA 01/2017
1	Gefitinib (Iressa)FDA Link 01/2017
1	Capecitabine (Xeloda)FDA Link 01/2014

Therapy/Procedure

1	Therapeutics 08/2018
1	Radiotherapy 01/2014
1	Chemoradiotherapy 01/2014